Summary: Week of 9/13/25
Biobot’s national wastewater network shows that COVID-19 is decreasing in week 37 (through September 13, 2025). Influenza A and RSV are holding steady at very low levels, while influenza B is fluctuating slightly at low levels. National hospitalizations for COVID-19 are increasing, currently at 2.5 per 100,000 people in week 36 (through September 6). RSV hospitalizations are holding steady at very low levels, currently 0.1 per 100,000 people while flu hospitalizations have not been updated on the CDC website since May 3rd.
The Bottom Line: COVID-19 activity is decreasing for the first time during this summer wave, while flu and RSV remain very low.
National Outlook
COVID-19
National SARS-CoV-2 concentrations are decreasing.
Influenza
National flu A concentrations are holding steady at very low levels, while influenza B is fluctuating slightly at very low levels.
RSV
National RSV concentrations are holding steady at very low levels.
Regional
The South
COVID-19: SARS-CoV-2 concentrations are decreasing in the South.
Influenza: Influenza A concentrations are holding steady at very low levels in the South, and influenza B concentrations are slightly increasing.
RSV: RSV concentrations are holding steady at very low levels in the South.
The Midwest
COVID-19: SARS-CoV-2 concentrations are decreasing in the Midwest.
Influenza: Influenza A and B concentrations are holding steady at very low levels in the Midwest.
RSV: RSV concentrations are holding steady at very low levels in the Midwest.
The Northeast
COVID-19: SARS-CoV-2 concentrations are decreasing in the Northeast.
Influenza: Influenza A & B are holding steady at very low levels in the Northeast.
RSV: RSV concentrations are holding steady at very low levels in the Northeast.
The West
COVID-19: SARS-CoV-2 concentrations are decreasing in the West.
Influenza: Influenza A and B concentrations are holding steady at very low levels in the West.
RSV: RSV concentrations are holding steady at very low levels in the West.
Footnotes:
We continue to monitor the evolving H5N1 influenza virus situation, and can now test samples specifically for H5 (including H5N1) — see our blog here and please reach out to hello@biobot.io if interested. A quick reminder that Biobot’s influenza A assay described in this report includes the H5N1 influenza subtype, which is an influenza A virus, but does not distinguish between the different subtypes of influenza A (e.g. H5N1 vs H1N1). We will share any important updates as we have them via Bluesky and in the risk reports.
Wastewater data from Biobot Analytics for RSV, influenza, and SARS-CoV-2 are through September 13, 2025 (MMWR week 37). Clinical data for RSV, influenza, and COVID-19 are from the Centers for Disease Control and Prevention. Updates to clinical data are through September 6, 2025 (MMWR week 36).